Olgu Sunumu
BibTex RIS Kaynak Göster
Yıl 2021, Cilt: 7 Sayı: 1, 150 - 153, 30.04.2021
https://doi.org/10.19127/mbsjohs.821860

Öz

Kaynakça

  • 1. Yanni EA, Ferreira G, Guennec M, El Hahi Y, El Ghachi A, Haguinet F, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. BMJ Open. 2018;7;8(6): e020528.
  • 2. Da Silva AMPS, De Moraes-Pinto MI, Succi RCM, Terreri MT, Machado DM. Clinical and Laboratory Characteristics of Herpes Zoster in Patients With HIV/AIDS and Those With Juvenile Systemic Lupus Erythematosus. Pediatr Infect Dis J. 2020;39(7):624-627.
  • 3. Jansen K, Haastert B, Michalik C, Guignard A, Esser S, Dupke S, et al. Incidence and risk factors of herpes zoster among hiv-positive patients in the german competence network for HIV/AIDS (KompNet): a cohort study analysis. BMC Infect Dis. 2013;10;13:372.
  • 4. Karadag AS, Elmas OF, Altunay IK. Cutaneous manifestations associated with HIV infections: A great imitator. Clin Dermatol. 2020;38(2):160-175.
  • 5. Claasens S, Kannenberg S, Jordaan H. F, Moxley K, Smith R, de Wet J, & Visser W. I. The prevalence and spectrum of mucocutaneous disease in South African people living with HIV and accessing care at a district-level hospital. Southern African journal of HIV medicine,2020; 21(1), 1154.
  • 6. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;10;4(6):e004833.
  • 7. John AR, Canaday DH. Herpes Zoster in the Older Adult. Infect Dis Clin North Am, 2017;;31(4):811-826.
  • 8. Kim YJ, Lee CN, Lee MS, Lee JH, Lee JY, Han K, et al. Recurrence Rate of Herpes Zoster and Its Risk Factors: a Population-based Cohort Study. J Korean Med Sci. 2018;20;34(2):e1 9. Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc. 2011,;86(2):88-93.
  • 10. Lee Y-T, Nfor ON, Tantoh DM, Huang J-Y, Ku W-Y, Hsu S-Y, et al. Herpes Zoster as a Predictor of HIV Infection in Taiwan: A Population- Based Study. PLoS ONE, 2015;10(11): e0142254.
  • 11. Barnabas RV, Baeten JM, Lingappa JR, Thomas KK, Hughes JP, Mugo NR, et al. Partners in Prevention HSV/HIV Transmission Study Team. Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial. J Infect Dis. 2016;213(4):551-5.
  • 12. Draganescu M, Baroiu L, Iancu A, Dumitru C, Radaschin D, Polea E. D, et al. Perspectives on skin disorder diagnosis among people living with HIV in southeastern Romania. Experimental and therapeutic medicine, 2021;21(1), 97.
  • 13. Lewis DJ, Schlichte MJ, Dao H Jr. Atypical disseminated herpes zoster: management guidelines in immunocompromised patients. Cutis. 2017 ;100(5):321;324;330.

Recurrent Herpes Zoster as a Sign of HIV Infection

Yıl 2021, Cilt: 7 Sayı: 1, 150 - 153, 30.04.2021
https://doi.org/10.19127/mbsjohs.821860

Öz

Herpes Zoster is characterized with painful dermatomal blisters, which commonly seen in elderly or immuncompromised people. It is caused by varicella zoster virüs (VZV). HIV infection is known as a risk factor for herpes zoster and for developments of its complications. Cutaneous findings can be the presenting symptom for HIV infection. In the presence of HIV infection, HZ can be prolong or can complicate evet its recurrence rate increases. HZ recurrences are usually seen in immuncompromised individuals.
In the presence of HIV infection, the risk of HZ increases up to 12-17 fold. Prophylaxis with daily asiclovir decrease the risk of HZ by 68%. Vaccination for HZ was found safe and effective in HIV patients with CD4+ cell count more than 200 cells/. Skin findings are frequent in HIV patients and its diversity change according to the stages of the disease. Here we report a case of recurrent HZ which later diagnosed with positive for HIV, therefore, to mention HIV as a risk factor in cases of recurrent HZ. 

Kaynakça

  • 1. Yanni EA, Ferreira G, Guennec M, El Hahi Y, El Ghachi A, Haguinet F, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. BMJ Open. 2018;7;8(6): e020528.
  • 2. Da Silva AMPS, De Moraes-Pinto MI, Succi RCM, Terreri MT, Machado DM. Clinical and Laboratory Characteristics of Herpes Zoster in Patients With HIV/AIDS and Those With Juvenile Systemic Lupus Erythematosus. Pediatr Infect Dis J. 2020;39(7):624-627.
  • 3. Jansen K, Haastert B, Michalik C, Guignard A, Esser S, Dupke S, et al. Incidence and risk factors of herpes zoster among hiv-positive patients in the german competence network for HIV/AIDS (KompNet): a cohort study analysis. BMC Infect Dis. 2013;10;13:372.
  • 4. Karadag AS, Elmas OF, Altunay IK. Cutaneous manifestations associated with HIV infections: A great imitator. Clin Dermatol. 2020;38(2):160-175.
  • 5. Claasens S, Kannenberg S, Jordaan H. F, Moxley K, Smith R, de Wet J, & Visser W. I. The prevalence and spectrum of mucocutaneous disease in South African people living with HIV and accessing care at a district-level hospital. Southern African journal of HIV medicine,2020; 21(1), 1154.
  • 6. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;10;4(6):e004833.
  • 7. John AR, Canaday DH. Herpes Zoster in the Older Adult. Infect Dis Clin North Am, 2017;;31(4):811-826.
  • 8. Kim YJ, Lee CN, Lee MS, Lee JH, Lee JY, Han K, et al. Recurrence Rate of Herpes Zoster and Its Risk Factors: a Population-based Cohort Study. J Korean Med Sci. 2018;20;34(2):e1 9. Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc. 2011,;86(2):88-93.
  • 10. Lee Y-T, Nfor ON, Tantoh DM, Huang J-Y, Ku W-Y, Hsu S-Y, et al. Herpes Zoster as a Predictor of HIV Infection in Taiwan: A Population- Based Study. PLoS ONE, 2015;10(11): e0142254.
  • 11. Barnabas RV, Baeten JM, Lingappa JR, Thomas KK, Hughes JP, Mugo NR, et al. Partners in Prevention HSV/HIV Transmission Study Team. Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial. J Infect Dis. 2016;213(4):551-5.
  • 12. Draganescu M, Baroiu L, Iancu A, Dumitru C, Radaschin D, Polea E. D, et al. Perspectives on skin disorder diagnosis among people living with HIV in southeastern Romania. Experimental and therapeutic medicine, 2021;21(1), 97.
  • 13. Lewis DJ, Schlichte MJ, Dao H Jr. Atypical disseminated herpes zoster: management guidelines in immunocompromised patients. Cutis. 2017 ;100(5):321;324;330.
Toplam 12 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Olgu Sunumu
Yazarlar

Fatma Etgü 0000-0003-1214-3327

Yayımlanma Tarihi 30 Nisan 2021
Yayımlandığı Sayı Yıl 2021 Cilt: 7 Sayı: 1

Kaynak Göster

Vancouver Etgü F. Recurrent Herpes Zoster as a Sign of HIV Infection. Middle Black Sea Journal of Health Science. 2021;7(1):150-3.

22104 22108 22107 22106 22105 22103 22109   22137  2210222110     e-ISSN 2149-7796